GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Revolution Medicines Inc (FRA:42Z) » Definitions » EV-to-FCF

Revolution Medicines (FRA:42Z) EV-to-FCF : -10.63 (As of May. 20, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Revolution Medicines EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Revolution Medicines's Enterprise Value is €4,496.56 Mil. Revolution Medicines's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2024 was €-422.84 Mil. Therefore, Revolution Medicines's EV-to-FCF for today is -10.63.

The historical rank and industry rank for Revolution Medicines's EV-to-FCF or its related term are showing as below:

FRA:42Z' s EV-to-FCF Range Over the Past 10 Years
Min: -35.88   Med: -8.37   Max: -4.17
Current: -10.67

During the past 7 years, the highest EV-to-FCF of Revolution Medicines was -4.17. The lowest was -35.88. And the median was -8.37.

FRA:42Z's EV-to-FCF is ranked worse than
100% of 378 companies
in the Biotechnology industry
Industry Median: 8.59 vs FRA:42Z: -10.67

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-20), Revolution Medicines's stock price is €35.80. Revolution Medicines's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was €-3.531. Therefore, Revolution Medicines's PE Ratio for today is At Loss.


Revolution Medicines EV-to-FCF Historical Data

The historical data trend for Revolution Medicines's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Revolution Medicines EV-to-FCF Chart

Revolution Medicines Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-FCF
Get a 7-Day Free Trial - -21.64 -8.82 -6.69 -8.26

Revolution Medicines Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -6.01 -8.22 -7.60 -8.26 -8.08

Competitive Comparison of Revolution Medicines's EV-to-FCF

For the Biotechnology subindustry, Revolution Medicines's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Revolution Medicines's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Revolution Medicines's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Revolution Medicines's EV-to-FCF falls into.



Revolution Medicines EV-to-FCF Calculation

Revolution Medicines's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=4496.563/-422.837
=-10.63

Revolution Medicines's current Enterprise Value is €4,496.56 Mil.
Revolution Medicines's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-422.84 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Revolution Medicines  (FRA:42Z) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Revolution Medicines's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=35.80/-3.531
=At Loss

Revolution Medicines's share price for today is €35.80.
Revolution Medicines's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-3.531.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Revolution Medicines EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Revolution Medicines's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Revolution Medicines (FRA:42Z) Business Description

Traded in Other Exchanges
Address
700 Saginaw Drive, Redwood City, CA, USA, 94063
Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products include RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio, and SOS1 and 4EBP1/mTORC1 programs.

Revolution Medicines (FRA:42Z) Headlines

No Headlines